1,416
Views
0
CrossRef citations to date
0
Altmetric
Original Research

A projected cost-utility analysis of avacopan for the treatment of antineutrophil cytoplasmic antibody-associated vasculitis in Spain

, , , , , & show all
Pages 227-235 | Received 27 Oct 2023, Accepted 15 Dec 2023, Published online: 25 Dec 2023

Reprints and Permissions

Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.

To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.

For more information please visit our Permissions help page.